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Summary
Background—Estimates of incidence of switching to second-line antiretroviral therapy (ART) 
among children with HIV are necessary to inform the need for paediatric second-line 
formulations. We aimed to quantify the cumulative incidence of switching to second-line ART 
among children in an international cohort collaboration.
Methods—In this international cohort collaboration study, we pooled individual patient-level 
data for children younger than 18 years who initiated ART (two or more nucleoside reverse-
transcriptase inhibitors [NRTI] plus a non-NRTI [NNRTI] or boosted protease inhibitor) between 
1993 and 2015 from 12 observational cohort networks in the Collaborative Initiative for Paediatric 
HIV Education and Research (CIPHER) Global Cohort Collaboration. Patients who were reported 
to be horizontally infected with HIV and those who were enrolled in trials of treatment 
monitoring, switching, or interruption strategies were excluded. Switch to second-line ART was 
defined as change of one or more NRTI plus either change in drug class (NNRTI to protease 
inhibitor or vice versa) or protease inhibitor change, change from single to dual protease inhibitor, 
or addition of a new drug class. We used cumulative incidence curves to assess time to switching, 
and multivariable proportional hazards models to explore patient-level and cohort-level factors 
associated with switching, with death and loss to follow-up as competing risks.
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Findings—At the data cutoff of Sept 16, 2015, 182 747 children with HIV were included in the 
CIPHER dataset, of whom 93 351 were eligible, with 83 984 (90·0%) from sub-Saharan Africa. At 
ART initiation, the median patient age was 3·9 years (IQR 1·6–6·9) and 82 885 (88·8%) patients 
initiated NNRTI-based and 10 466 (11·2%) initiated protease inhibitor-based regimens. Median 
duration of follow-up after ART initiation was 26 months (IQR 9–52). 3883 (4·2%) patients 
switched to second-line ART after a median of 35 months (IQR 20–57) of ART. The cumulative 
incidence of switching at 3 years was 3·1% (95% CI 3·0–3·2), but this estimate varied widely 
depending on the cohort monitoring strategy, from 6·8% (6·5–7·2) in settings with routine 
monitoring of CD4 (CD4% or CD4 count) and viral load to 0·8% (0·6–1·0) in settings with clinical 
only monitoring. In multivariable analyses, patient-level factors associated with an increased 
likelihood of switching were male sex, older age at ART initiation, and initial NNRTI-based 
regimen (p<0·0001). Cohort-level factors that increased the likelihood of switching were higher-
income country (p=0·0017) and routine or targeted monitoring of CD4 and viral load (p<0·0001), 
which was associated with a 166% increase in likelihood of switching compared with CD4 only 
monitoring (subdistributional hazard ratio 2·66, 95% CI 2·22–3·19).
Interpretation—Our global paediatric analysis found wide variations in the incidence of 
switching to second-line ART across monitoring strategies. These findings suggest the scale-up of 
viral load monitoring would probably increase demand for paediatric second-line ART 
formulations.
Introduction
In 2017, an estimated 1·8 million children (younger than 15 years) were living with HIV 
worldwide, of whom 52% had access to antiretroviral therapy (ART).1 A concerted effort 
will be needed to achieve the ambitious UNAIDS 90–90-90 goals to end AIDS by 2020 
among children: ensuring that 90% of children living with HIV are diagnosed, 90% of those 
diagnosed are on ART, and 90% of those on ART attain and maintain viral suppression.2 
Children and adolescents have persistently lagged behind adults in their progress towards the 
first two 90% targets,3 leading to increased efforts to expand access to HIV diagnosis and 
ART for children across a variety of clinical settings in several countries.4 As more children 
receive ART and treatment programmes mature, development of strategies to meet the third 
90% target of sustained viral suppression will be the long-term challenge. Achievement of 
this goal requires a comprehensive understanding of the durability of first-line ART 
regimens and patterns of switching to second-line ART across geographical regions and 
different country-income settings to ensure future treatment needs are met.5
The short-term effectiveness of ART in children is undisputed, with high survival, immune 
and growth recovery, and the proportion of patients with a suppressed viral load at 12 
months after initiation of ART ranging from 70% to 95%.6–8 Comparatively less data are 
available on the durability of first-line ART and the use of second-line treatment in children. 
The PENPACT trial,9 which comprised patients from predominately high-income countries, 
reported that 71% (188 of 266) of children remained on their first-line regimen 5 years after 
starting ART, compared with 95% or more of children in the CHER8 and ARROW7 trials 
that comprised children from Africa. Observational cohorts have reported wide variations in 
the probability of switching to second-line ART after treatment failure, with the definition of 
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treatment failure varying between studies. One large South African observational cohort10 
reported that 19% of children (Kaplan-Meier estimate, 95% CI 18–21) had virological 
failure 3 years after initiation of ART. Among the 252 children with 1 year or more of 
follow-up after virological failure, 38% (95% CI 32–45) switched to second-line ART. In a 
west African cohort,11 322 (12%) of 2676 children with HIV had clinical-immunological 
failure after 24 months of ART, of whom 21 (7%) switched to second-line ART. Other 
cohort studies in Asia12 and Europe13 have reported a 17–23% probability of children 
switching to second-line ART by 5 years after initiation of ART. Comparison across these 
studies is difficult because of the heterogeneity of patients’ characteristics, initial ART 
regimens, monitoring strategies, and the varying definitions of treatment failure and 
switching.
We aimed to provide the first global estimates of the incidence of switching to second-line 
ART among children with HIV using a uniform definition of switching, and to assess 
associated factors (ie, patient-level and cohort-level factors). This analysis is a key step in 
understanding the use of second-line regimens globally and across programmes that operate 
under various strategies for treatment monitoring and guidelines for switching to second-line 
ART.
Methods
Study design and population
In this international cohort collaboration study, we pooled data from the Collaborative 
Initiative for Paediatric HIV Education and Research (CIPHER) network. CIPHER is a 
global network of observational paediatric HIV cohorts. The collaboration includes 12 
international networks: Baylor International Pediatric AIDS Initiative (BIPAI); European 
Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC); the International 
Epidemiology Databases to Evaluate AIDS (IeDEA) Consortium, comprising IeDEA Asia-
Pacific, IeDEA Central Africa, IeDEA East Africa, IeDEA Southern Africa, IeDEA West 
Africa, and Caribbean, Central and South America network (CCASAnet); International 
Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) 219C and P1074; 
Médecins Sans Frontières (MSF); Optimal Models (ICAP at Columbia University); and 
Pediatric HIV/AIDS Cohort Study (PHACS). The network covers 52 countries and most 
networks comprised multiple cohorts and each cohort included data from one or more clinics 
(primary care clinic, primary community clinic, or hospital).
We pooled individual participant-level data from the CIPHER dataset for patients younger 
than 10 years at enrolment (a proxy for perinatal HIV infection), younger than 18 years at 
initiation of a standard combination ART regimen (ie, at least three antiretroviral drugs, 
including at least two nucleoside reverse-transcriptase inhibitors [NRTIs] plus either a non-
NRTI [NNRTI] or a ritonavir-boosted protease inhibitor) between Jan 1, 1993, and Sept 1, 
2015, and with 1 day or more of follow-up after initiation of ART. Patients who were 
reported to be horizontally infected and those enrolled in clinical trials of treatment 
monitoring, switching, or interruption strategies were excluded.
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Individual patient-level data were sent to the University of Cape Town (Cape Town, South 
Africa) for data cleaning and data management using a standardised protocol based on the 
HIV Cohorts Data Exchange Protocol. The dataset was then sent to the University College 
London (London, UK) for analysis.
All participating networks received local ethics approvals to transfer anonymised data for 
this study. The pooling of data at the University of Cape Town was approved by the 
University of Cape Town Health Research Ethics Committee (UCT HREC [reference 
264/2014]).
Outcomes
The main study outcome was cumulative incidence of all-cause switching to second-line 
ART from first-line ART for any reason (hereafter referred to as switching). Switching was 
defined as change of one or more NRTI plus either change in drug class (NNRTI to protease 
inhibitor or vice versa) or protease inhibitor change, change from single to dual protease 
inhibitor, or addition of a new drug class. With this definition we endeavoured to capture 
major treatment changes because of treatment failure or major toxic side-effects of drugs 
and allow for comparisons with previous analyses of switching in children that used similar 
approaches.12,13
Statistical analysis
We explored cohort-level and patient-level potential predictors for switching. We generated 
cohort-level factors, which were geographical region, treatment monitoring strategy, and 
country-income group. The geographical regions with eligible data were categorised as 
Europe, the USA, Asia, Latin America (ie, the Caribbean, and Central and South America), 
southern Africa, and the rest of sub-Saharan Africa. Southern Africa was defined as 
Botswana and South Africa and was considered separate from the rest of sub-Saharan Africa 
because lopinavir-based regimens were introduced in 2010 as first-line ART for children 
younger than 3 years in Botswana and South Africa and are not part of the standardised first-
line regimen in the rest of sub-Saharan Africa, and Botswana and South Africa also had 
early roll-out of routine viral load monitoring in 2007–08,14,15 unlike the rest of sub-Saharan 
Africa.16
Strategies for treatment monitoring were assigned at the cohort level according to the 
presence and frequency of measurements of CD4 (CD4% or CD4 count) and viral load. 
Cohorts were classified as having routine monitoring of CD4 or viral load if more than 60% 
of children had one or more measurement of CD4 or viral load after initiation of ART and 
the median time between consecutive measurements was fewer than 60 weeks. Cohorts were 
classified as having targeted monitoring of CD4 or viral load if 5–60% of children had one 
or more measurements of CD4 or viral load after initiation of ART, or if more than 60% of 
children had one or more measurements but consecutive measures were more than 60 weeks 
apart. On the basis of these definitions, cohorts were classified into four groups: routine 
monitoring of CD4 and viral load, routine monitoring of CD4 and targeted monitoring of 
viral load, routine monitoring of CD4 only (<5% of children with viral load measurements), 
or clinical monitoring only (ie, targeted monitoring of CD4 only, or <5% of participants 
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have measurements of CD4 and viral load). Country-income groups were assigned by use of 
the World Bank classification17 (high-income and upper-middle-income, lower-middle-
income, or low-income economies) at the median year of ART initiation in the cohort.
For the HIV Cohorts Data Exchange Protocol website see http://www.hicdep.org
We investigated the following patient-level independent variables measured at ART 
initiation: sex, age (<3, 3–5, 6–9, and ≥10 years), known previous AIDS diagnosis (WHO 
stage 3–4 or US Centres for Disease Control and Prevention stage C; yes or no), initial ART 
regimen (protease inhibitor or NNRTI based), and calendar year (≤2004, 2005–2007, 2008–
2010, and ≥2011). We also collected data on bodyweight and CD4% or CD4 count at 
initiation of ART where available.
We calculated the weight-for-age Z scores relative to the 1990 British Growth Reference 
values in Stata18 (≤−2, >−2 to 0, and >0) and immunodeficiency for age with the WHO 
standard definition19 based on CD4% or CD4 cell count. Conventionally, CD4% is reported 
for children younger than 5 years and CD4 count is reported for children aged 5 years and 
older. No immunodeficiency is defined as CD4% over 35% for those younger than 12 
months, over 30% for those aged 12–35 months, or over 25% for those aged 36–59 months, 
and a CD4 count of over 500 cells per μL for those aged 5 years or older; mild 
immunodeficiency is defined as CD4% of 30–35% for those younger than 12 months, 25–
30% for those aged 12–35 months, or 20–25% for those aged 36–59 months, and a CD4 
count of 350–499 cells per μL for those aged 5 years or older; advanced immunodeficiency 
is defined as CD4% of 25–29% for those aged 12 months or younger, 20–24% for those 
aged 12–35 months, or 15–19% for those aged 36–59 months, and a CD4 count of 200–349 
cells per μL for those aged 5 years or older; and severe immunodeficiency is defined as 
CD4% less than 25% for those younger than 12 months, less than 20% for those aged 12–35 
months, or less than 15% for those aged 35–59 months, and a CD4 count of less than 200 
cells per μL for those aged 5 years or older.
We used descriptive statistics to illustrate the patient-level and cohort-level characteristics at 
ART initiation.
Patients were censored at the earliest of the following: switching to second-line ART, death, 
last visit, or 21st birthday. We summarised the cumulative incidence of switching allowing 
for the competing risks of death and loss to follow-up.20 Cumulative incidence of switching 
at 3 years after initiation of ART was stratified by geographical region, initial ART regimen, 
and cohort monitoring strategy.
Patients were considered as lost to follow-up if they had no visit data for 1 year or more 
before our study data inclusion cutoff (Sept 16, 2015), except for cohorts in the EPPICC, 
PHACS, and IMPAACT networks, for which a cutoff of 2 years or more was used because 
data collection for these cohorts is done annually and to account for time lags in reporting. 
We administratively censored follow-up of children at the date of last clinic visit. 
Additionally, we administratively censored patients who transferred to a different clinical 
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site not part of a participating cohort during their follow-up or if they were transferred to 
adult care.
We summarised the independent associations between cumulative incidence of switching 
and patient characteristics at initiation of ART and cohort characteristics by subdistribution 
hazard ratios calculated using multivariable competing-risks proportional hazards regression.
21
Additionally, the number of children in southern Africa younger than 3 years at the time of 
initiating a lopinavir-based regimen who switched to an NNRTI-based second-line regimen 
aged 3 years or older is reported and their viral load at time of switching summarised.
We did two sensitivity analyses. First, to assess the potential association between low 
weight-for-age Z score, immunosuppression at initiation of ART, and likelihood of 
switching. We repeated the regression models using patient-level data from a subset of 
cohorts in which more than 60% of children had bodyweight and CD4 measurements at 
ART initiation, and did the multivariable analysis with and without weight-for-age Z score 
and immunodeficiency for age.
In the second sensitivity analysis, we repeated all analyses redefining switching to second-
line ART by removing the requirement for a simultaneous change of one or more NRTI 
when changing across drug class (NNRTI to protease inhibitor or vice versa) or within the 
protease inhibitor drug class.
We did all analyses using Stata version 14.2.
Role of the funding source
The funder of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to all the 
data in the study and had final responsibility for the decision to submit for publication.
Results
At the time of data cutoff, Sept 16, 2015, the CIPHER dataset comprised patient-level data 
on 182 747 children living with HIV, of whom 93 351 (51%) met our inclusion criteria 
(appendix p 20). 12 networks covering 52 countries in the CIPHER database had eligible 
children, and most children were in the rest of sub-Saharan Africa (71%), with 19·1% in 
southern Africa, 6·6% in Asia, and the remaining 3·5% in Europe, Latin America, and the 
USA (figure 1). The calendar year of ART initiation ranged from 1993 to 2015, with over 
70% of children initiating ART in 2008 or later (table 1). Half of patients were male, and the 
median age at ART initiation was 3·9 years (IQR 1·6–6·9), with two-thirds aged 5 years or 
younger. The median age at ART initiation was similar across all regions, except for in the 
USA where the median age was younger than 1 year. 40 261 (43·1%) children had known 
AIDS diagnosis at ART initiation, and among 50 892 (54·5%) children with available CD4 
data, 37 962 (74·6%) had advanced or severe immunodeficiency, with Asia and southern 
Africa having the highest proportions of patients with severe immunodeficiency.
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82 885 (88·8%) children initiated an NNRTI-based regimen (61 664 [66·1%] on nevirapine), 
although regional variations were observed (table 1; appendix p 21). In southern Africa, 
6803 (84%) of 8082 patients younger than 3 years at ART initiation were initiated on a 
ritonavir-boosted lopinavir-based regimen compared with 1262 (4·5%) of 27 856 in the rest 
of sub-Saharan Africa (appendix p 22).
Strategies for treatment monitoring also varied between the geographical regions. In the 
USA, Europe, and southern Africa, almost all patients were in cohorts with routine 
monitoring of CD4 and viral load, whereas in Asia 56% of patients were in cohorts with 
routine monitoring of CD4 and viral load and 40% were in cohorts with routine monitoring 
of CD4 and targeted monitoring of viral load. In the rest of sub-Saharan Africa, only 3·0% 
of patients were in cohorts with routine monitoring of CD4 and viral load, equal proportions 
of patients (21·4%) were in cohorts with routine monitoring of CD4 and targeted monitoring 
of viral load and in cohorts with clinical monitoring only, and 54·1% were in cohorts with 
only CD4 monitoring.
Median duration of follow-up after ART initiation was 26 months (IQR 9–52), with longer 
follow-up in regions outside of Africa (table 2). At data cutoff (without use of competing 
risks and ignoring switching to second-line ART) 5417 (5·8%) patients had died, 13 846 
(14·8%) were lost to follow-up and not known to have died, 19 888 (21·3%) had transferred 
to another clinic or to adult care, and 54 200 (58·1%) were still in follow-up.
Over 265 942 person-years of follow-up, 4·2% of patients met our definition of switching to 
second-line ART, and on the basis of our competing-risk analysis 0·5% died, 19·6% were 
lost to follow-up, and 20·7% transferred before switching. The crude rate of switching was 
14·6 switches per 1000 person-years (95% CI 14·1–15·1). The cumulative incidence of 
switching by 3 years after initiation of ART was 3·1% (95% CI 3·0–3·2), with wide variation 
between geographical region, initial regimen, and monitoring strategies (table 2, figure 2A). 
The cumulative incidences of switching by 1, 2, and 3 years after initiation of ART stratified 
by these variables are shown in the appendix (pp 14–15). We found the highest incidence of 
switching to be among children who initiated ART on NNRTI-based regimens in the USA 
and the lowest incidence among children on NNRTI-based regimens in sub-Saharan Africa 
with CD4 or clinical only monitoring. Among children who started ART in 2011 or later, 
similar variations in the incidence of switching across treatment monitoring strategies was 
observed (appendix p 15). Because the rest of sub-Saharan Africa was the only region that 
used all four types of monitoring strategy, we further explored the cumulative incidence of 
switching within this region (figure 2B) and found the cumulative incidence of switching at 
3 years to be 6·1% (95% CI 5·0–7·4) in cohorts with routine monitoring of CD4 and viral 
load compared with less than 2% (table 2) in cohorts with no viral load monitoring.
Among the 3883 children who switched to second-line ART, the median time to switch was 
35 months (IQR 20–57; appendix pp 18–19). The median age at switch was 8·6 years (IQR 
5·5–11·5), and 3329 (85·7%) switches were from an NNRTI-based to a protease inhibitor-
based regimen, 419 (10·8%) were from a protease inhibitor-based to an NNRTI-based 
regimen, and 135 (3·5%) were other switches. Among children with recorded CD4% or CD4 
cell counts at the time of switch (n=3016), 1265 (41·9%) had severe immunodeficiency and 
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359 (11·9%) had advanced immunodeficiency. Among the 2419 (62·3%) patients with 
measurements of viral load at the time of switching, 2013 (83·2%) had a viral load of more 
than 1000 copies per mL. 203 (5%) patients had a tuberculosis diagnosis at the time of 
switching. 75 children younger than 3 years at the start of lopinavir-based first-line ART 
switched to an NNRTI-based second-line ART when older than 3 years and while virally 
suppressed to under 1000 copies per mL. Among the 2219 (57%) patients with a reported 
reason for switching, 1132 (51%) switched because of treatment failure, 67 (3%) because of 
toxic side-effects of drugs, and 1020 (46%) because of other (unspecified) reasons.
In our multivariable analyses, individual patient-level factors associated with an increased 
likelihood of switching were male sex, older age at ART initiation, initiation of ART on an 
NNRTI-based regimen, and earlier calendar year of initiation of ART (table 3). In the 
multivariable analysis of cohort-level factors associated with switching, treatment 
monitoring strategy was indentified as a factor. Compared with monitoring of CD4 only, 
routine CD4 and viral load monitoring was associated with a 166% increase in the likelihood 
of switching, whereas clinical only monitoring was associated with a 32% decrease in 
likelihood (table 3). High-income and upper-middle-income countries were associated with 
an increased likelihood of switching compared with low-income countries. All geographical 
regions outside of Africa had increased likelihoods of switching compared with southern 
Africa, whereas we saw no difference between southern Africa and the rest of sub-Saharan 
Africa.
In the first sensitivity analysis, which was restricted to patient-level data from a subset of 
cohorts that recorded CD4% or CD4 cell count and bodyweight at ART initiation in over 
60% of participants (n=39 724), the risk factors for switching remained consistent with the 
main analyses, except for some differences in the effect of the geo graphical region. Patients 
in the rest of sub-Saharan Africa had a decreased likelihood of switching compared with 
those in southern Africa. The association between country-level incomes was no longer 
present (table 3). Additionally, patients with severe immunodeficiency had an increased 
likelihood of switching compared with those with advanced immunodeficiency, but we saw 
no association between switching and weight-for-age Z score at initiation of ART.
In the second sensitivity analysis that broadened the definition of switching, the number of 
patients who met the definition increased from 3883 (4·2%) to 4035 (4·3%). Most of the 
additional switches were from an NNRTI-based to a protease inhibitor-based regimen. 
Factors associated with switching and hazard estimates were broadly similar to those 
identified in the main analyses (appendix pp 16–17).
Discussion
The incidence of switching to second-line ART among children with HIV≠≠ was 14·6 
switches per 1000 person-years with a cumulative incidence of 3·1% by 3 years after 
initiation of ART. However, we identified large variations between individual patient 
characteristics, geographical regions, and by cohort monitoring strategies.
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3 years after initiation of ART, the cumulative incidence of switching was lowest among 
patients in cohorts in the rest of sub-Saharan Africa with clinical only monitoring, and was 
only slightly increased in this region when monitoring of CD4 was available. These 
estimates are lower than the median proportion of patients who switched after 4 years of 
follow-up reported in the ARROW trial (63 [5%] of 1206),7 which was conducted in the rest 
of sub-Saharan Africa where all patients initiated NNRTI-based regimens and were managed 
with only clinical or CD4 monitoring. However, because ARROW is a clinical trial, patients 
were followed up more closely than they might be in routine care, and the median duration 
of follow-up in ARROW (4 years [IQR 3·7–4·4]) was longer than in our cohort. WHO 
forecasting models estimate that the proportion of children with HIV on ART globally who 
are receiving second-line regimens, irrespective of duration on ART, was 4·1% in 2013 and 
increased to 6·1% in 2015.22 However, these estimates are cross-sectional and based on 
extrapolations from historical trends in global antiretroviral procurement data and 
projections from assumptions regarding ART coverage. Therefore, the estimates cannot be 
directly compared with our estimates of cumulative incidence of switching to second-line 
ART at 3 years after initiation of ART.
In our analysis, patients who were managed in settings that monitored their viral load were 
twice as likely to switch to second-line ART compared with children in settings that only 
had access to CD4 or clinical monitoring, or both. This finding is consistent with findings 
from adult HIV modelling studies23 that estimate that the number of patients receiving 
second-line ART in settings with rapid scale-up of viral load monitoring will increase two to 
three times compared with slow or no scale-up of viral load monitoring.
Studies24,25 have reported that 20–40% of children with only clinical or CD4 monitoring 
had evidence of virological failure (viral load ≥1000 copies per mL) at 3–4 years after 
initiation of ART, highlighting the poor sensitivity of these monitoring strategies in detecting 
virological failure. This issue is particularly important in sub-Saharan Africa where most 
children initiate ART on NNRTI-based regimens with low genetic thresholds for resistance.
26
 Although the PENPACT-1 trial9 reported no difference in clinical outcomes of children on 
NNRTI-based or protease inhibitor-based regimens who were assigned to switch to second-
line ART after virological failure at over 1000 copies per mL (early switch) or at over 10 
000 copies per mL (delayed switch), adult studies27,28 in sub-Saharan Africa have shown 
increased risks of morbidity and mortality in patients with delayed switching to second-line 
ART. A comparison of the clinical outcomes of children managed under a variety of 
monitoring strategies and time between treatment failure and switching is warranted to 
determine the best use of resources to obtain optimal outcomes in this population.
In our study, we estimated that most regions had a higher cumulative incidence of switching 
to second-line ART among children who initiated an NNRTI-based regimen than among 
those who initiated a protease inhibitor-based regimen. However, in the rest of sub-Saharan 
Africa we estimated a higher cumulative incidence of switching among children who 
initiated protease inhibitor-based regimens than those who initiated NNRTI-based regimens, 
although this estimate was based on a small proportion of children starting on protease 
inhibitors in that region (2·4%, all ritonavir-boosted lopinavir). Review of these data 
indicates that our finding might be partly because of incident tuberculosis and the need to 
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avoid protease inhibitors when initiating a tuberculosis treatment regimen containing 
rifampin. Because the tuberculosis data were incompletely reported, we could not 
completely explore this hypothesis. The finding that older age at initiation of ART is 
associated with an increased likelihood of switching has been previously reported11,13 and 
could be partly due to the lack of available paediatric formulations for young children and 
poorer adherence among adolescents than among younger children. The increased incidence 
of switching among male patients has been previously reported in paediatric and adult 
cohorts,11,12,29 and warrents further study.
Our analysis suggested that even after adjusting for monitoring strategy and patient-level 
characteristics, being in the rest of sub-Saharan Africa and in low-income countries 
remained independently associated with a decreased likelihood of switching to second-line 
therapy. The comparatively less frequent use of second-line ART in such settings, even when 
viral load monitoring was available, could partly be because of the higher thresholds for 
virological failure recommended by WHO for low-income and middle-income countries 
than for high-income and upper-middle-income countries.30 This finding could also reflect 
the paucity of access to second-line drugs and clinicians’ fears about availability of 
subsequent third-line therapy, although these factors were not measured in our study.
The low global cumulative incidence of switching to second-line ART reported in our 
analysis, which was dominated by a large number of children in southern Africa and the rest 
of sub-Saharan Africa, reflects standard practice for those who intitated ART between 1993 
and 2015 in participating programmes. Since 2015, scale-up of viral load monitoring has 
been ongoing and is likely to substantially increase the early detection of treatment failure 
and demand for second-line ART. However, the extent of the increase in demand for second-
line ART across settings remains unclear and will still be subject to local resources and 
guidance. Although less guidence and data exist on the optimal use of the low-cost integrase 
inhibitor dolutegravir in second-line ART in children, its roll-out as first-line and second-line 
ART in adults will probably lead to increased call for its use in children.31 Because our 
study spans a large age spectrum and time period, it provides crucial insight into how 
clinicians have assessed and responded to first-line treatment failure in children on ART to 
date. These insights can be of use both to forecast future paediatric ART needs and to 
identify settings in which the system might be failing children and potential points of 
intervention. Future assessments of the durability of first-line regimens in-line with when 
new drugs are rolled out will be crucial to ensure sufficient availability of paediatric 
formulations in the future.
This study had several limitations. First, few cohorts reported data on the reasons for ART 
switch, and among those that did report reasons almost half of the reasons were unspecified 
as other reasons. Furthermore, few cohorts had data on viral load at the time of switching, 
and so we could not elucidate whether the switch was because of treatment failure. However, 
because of our conservative definition of switching to second-line ART, we feel that most of 
the switches were true switches to second-line ART rather than minor treatment 
modifications or simplifications. Since 2010 in South Africa, guidelines have recommended 
to switch children aged 3 years and older to an NNRTI-based regimen if they were younger 
than 3 years at initiation of a lopinavir-based ART regimen and if they were virally 
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suppressed.14 We considered that this recommendation might lead to overestimation of 
switches among this population; however, only 75 children were switched in this manner 
while virally suppressed, and thus their potential misclassification would not substantially 
affect our findings. Second, this is an observational study with sources of potential bias such 
as the high proportion of children lost to follow-up, which has probably resulted in 
incomplete ascertainment of switching and deaths. This limitation has been addressed in part 
by our use of a competing-risk analyses. Third, AIDS diagnoses might have been under-
reported at initiation of ART in some low-income country settings because of restricted 
capacity for clinical diagnostics. Data are also incomplete on co-infections (eg, tuberculosis) 
and the availability of alternative antiretroviral drugs restricted our ability to explore 
possible reasons for the geographical variations in switching patterns. Finally, although this 
is a large global cohort collaboration, we are still extrapolating data from a finite number of 
cohorts to a global estimate.
For CIPHER website see http://www.iasociety.org/CIPHER
In conclusion, we found that the cumulative incidence of switching to second-line ART 
varied widely between both geographical regions and by monitoring strategies. Given the 
maturing cohorts and expanding roll-out of viral load testing and new drugs, we anticipate 
that the use of second-line regimens will increase, although geographical variation will most 
likely persist for the foreseeable future. The effect of delayed versus fast switching to 
second-line ART after treatment failure on longer-term clinical outcomes and treatment 
options among children remain unclear and warrant further exploration.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Research in context
Evidence before this study
We searched PubMed for studies published in English from database inception to Nov 
16, 2017, that assessed the probability of switching to second-line antiretroviral therapy 
(ART) in children with HIV across geographical regions and under different monitoring 
strategies using the search terms “child”, “children”, OR “adolescent”; “HIV”, 
“antiretroviral therapy”, “switch”, AND “second-line”. We identified several clinical 
trials and several cohort studies that reported on the probability of switching that used 
various different definitions of switching. Few studies estimated the incidence of 
switching to second-line ART in children across several countries with different strategies 
of treatment monitoring. To our knowledge, no published global-level analysis of 
switching to second-line ART among children exists that uses a uniform definition of 
switching.
Added value of this study
This study provides the first global estimates of the incidence of switching to second-line 
ART, using individual patient-level data for over 93 000 children across 52 countries. We 
found a low cumulative incidence of switching of 3·1% by 3 years after initiation of ART 
globally, but with significant variations across geographical regions and by treatment 
monitoring strategies. Compared with CD4 (CD4% or CD4 cell count) or clinical only 
monitoring, children in settings with routine or targeted monitoring of viral load were 
twice as likely to switch to second-line ART.
Implications of all the available evidence
As HIV treatment programmes mature, understanding patterns in the use of second-line 
ART is crucial to ensure future needs of paediatric treatment are met. The wide variations 
in the incidence of switching to second-line ART across regions and monitoring 
strategies highlight the need to assess the effect of low rates of switching and prolonged 
treatment failure before switching on clinical outcomes in children and the potential 
implications of expanding access to viral load testing on future use of second-line ART in 
resource-limited settings.
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Figure 1: 
Geographical distribution of children with HIV included in study
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Figure 2: Cumulative incidence of switching to second-line ART among children at 3 years after 
ART initiation
(A) Incidence by region. (B) Incidence by monitoring strategy for sub-Saharan Africa 
(excluding Botswana and South Africa) only at 3 years after ART initiation. 
ART=antiretroviral therapy.
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